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Introduction
Intracellular communications involved in immune
responses are often mediated by cytokines that show a
high degree of redundancy and pleiotropy, controlling a
wide range of functions in various cell types. Disordered
expression of cytokines has been shown to play a role in
autoimmune diseases such as rheumatoid arthritis (RA). In
particular, abnormalities of TNF-α and such downstream
mediators of proinflamatory activity as IL-1, IL-6, granulo-
cyte/macrophage-colony-stimulating factor (GM-CSF),
and inflammatory chemokines have been demonstrated in
RA [1]. Recently, disorders involving interleukin (IL)-15
have been demonstrated in this autoimmune disease as
well [2–10]. IL-2 and IL-15 utilize heterotrimeric receptors
that include cytokine-specific private receptors IL-2Rα and
IL-15Rα respectively, as well as two receptor elements, IL-
2Rβ and γc, that they share [11–14]. We and others have
shown that although IL-2 and IL-15 share two receptors
and therefore share many functions, they also provide dis-
tinct and at times contrasting contributions to the life and
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death of lymphocytes [15–19]. IL-2, through its pivotal
role in activation-induced cell death (AICD), is involved in
peripheral tolerance through the elimination of self-reactive
T cells [20]. In contrast, IL-15 in general manifests anti-
apoptotic actions and inhibits AICD and stimulates the
persistence of memory phenotype CD8+ T cells [17,18].
Abnormalities of IL-15 expression have been reported in
inflammatory, autoimmune, and neoplastic diseases
[2–10,21–24]. In particular, abnormally high levels of IL-
15 transcription and translation are observed in human T-
cell lymphotropic virus I (HTLV-I)-associated diseases
such as the neurological disorder tropical spastic para-
paresis/HTLV-I associated myelopathy (TSP/HAM)
[23,24]. Furthermore, abnormalities of IL-15 expression
have been noted in patients with autoimmune diseases
such as RA and inflammatory bowel disease [2–10,
21–24]. Therapeutic agents are being developed to target
the receptor and signaling elements shared by IL-2 and IL-
15 to provide effective treatment for such autoimmune dis-
orders as well as the leukemia/lymphomas that are
associated with the retrovirus HTLV-I [9,10,19].
Historical background
Two separate groups simultaneously reported the recogni-
tion of the novel cytokine now known as IL-15, which was
recognized as novel on the basis of the ability of culture
supernatants from two cell lines, CV-1/EBNA and the
HTLV-I-associated HuT-102, to stimulate proliferation of
the cytokine-dependent murine T cell CTLL-2 in the
absence of IL-2 [12,13]. During studies to define patho-
genic mechanisms that underlie the IL-2-independent pro-
liferation of HTLV-I-associated adult T-cell leukemia cells,
our group found that the ATL (adult T-cell leukemia) cell
line HuT-102 secretes a 14–15-kDa lymphokine, which
we provisionally designated IL-T, that stimulates T-cell pro-
liferation and induces activation of large, granular lympho-
cytes [12,25]. In addition, we showed that IL-T-mediated
stimulation requires the expression of the IL-2Rβ subunit
[12]. Grabstein and co-workers simultaneously reported a
cytokine they designated IL-15, which was isolated from
the supernatant of the simian kidney epithelial-cell line
CV-1/EBNA [13]. IL-15 shared many characteristics with
IL-T, including an apparent molecular mass of 14–15 kDa,
as well as a signaling pathway in T and natural killer (NK)
cells that utilized the IL-2Rβ and γc subunits of the IL-2
receptor. By use of an appropriate anti-cytokine antibody,
IL-T and IL-15 were shown to be identical [19].
IL-2/IL-15 cytokine family
Cytokines exhibit a high degree of redundancy and
pleiotropy, which is explained in part by the sharing of
common receptor subunits among members of the
cytokine receptor family. Each cytokine has its own private
receptor, but may also share public receptor subunits with
other cytokines. This is the case in the IL-2 receptor
system. The IL-2R is made up of at least three distinct
membrane components: the 55-kDa alpha chain (IL-2Rα);
the 70–75-kDa β chain (IL-2Rβ); and the 64-kDa common
γ chain (γc) chain, which is shared with other members of
this system, including IL-4, IL-7, IL-9, IL-15, and IL-21. IL-2
and IL-15 also share the IL-2Rβ subunit [11–14].
The regulation of IL-15 expression
IL-2 and IL-15 exhibit major differences in the levels of
control of their synthesis and secretion and in their sites of
synthesis [19,26,27]. IL-2 is produced by activated T cells
and its expression is regulated predominantly at the levels
of mRNA transcription and message stabilization. In con-
trast, there is widespread constitutive expression of IL-15
mRNA in a variety of tissues, including placenta, skeletal
muscle, kidney, lung, heart, fibroblasts, and activated
monocytes [13,19].
The regulation of IL-15 expression is multifaceted. Modest
control occurs at the level of transcription, whereas a
dominant control occurs post-transcriptionally, at the
levels of translation and intercellular trafficking [19,26,28].
Although IL-15 mRNA is widely expressed constitutively, it
has been difficult to demonstrate IL-15 within the cells or
the supernatants of cells that express such IL-15 mRNA.
Multiple controlling elements impede the translation of
IL-15 mRNA, including a long 5′ UTR containing IL-13
upstream AUGs, an unusually long (48-amino-acid) IL-15
signal peptide, and an inhibitory element in the C terminus
of the IL-15 mature coding sequence or protein
[19,26,27]. These multiple negative regulatory features
controlling IL-15 expression may be required, in light of the
potency of IL-15 as an inflammatory cytokine that stimu-
lates the expression of TNF-α, IL-1β, and inflammatory
chemokines, which if indiscriminately expressed could
lead to inflammatory autoimmune diseases. In terms of a
more positive role for IL-15, by maintaining a pool of trans-
lationally inactive mRNA, cells may respond rapidly to an
intracellular infection by transforming the IL-15 mRNA into
a form that can be translated effectively, yielding secreted
IL-15 that may activate T and NK cells that could then aid
in the host response to the invading pathogen.
The shared and contrasting roles of IL-2 and
IL-15 in the life and death of lymphocytes
Functions mediated by IL-2 and IL-15 may be evaluated
with regard to the fundamental goals of the immune
system, which may be considered to include the genera-
tion of a rapid innate and adapative response to invading
pathogens; the maintenance of a specific memory
response to these pathogens; and the elimination of host-
reactive T cells, to yield tolerance to self.
As might be anticipated from their sharing of the IL-2Rβ
and γc subunits in T and NK cells, IL-15 and IL-2 share a
number of biological activities, including stimulation of the
proliferation of activated CD4+CD8+ as well as γδ subsetsS163
of T cells [19,29–31]. IL-2 and IL-15 also facilitate the
induction of cytolytic effector cells, including CTL and LAK
cells [19,29–31]. In addition, both IL-2 and IL-15 act as
chemoattractants for T cells. The two cytokines stimulate
the proliferation of NK cells and can synergize with IL-12
to facilitate their synthesis of IFN-γ and TNF-α [31]. Both
cytokines induce the proliferation and immunoglobulin syn-
thesis by human B cells stimulated with anti-IgM or CD40
ligand [32].
A major advance emerging from work in our laboratory and
those of others is that although IL-2 and IL-15 share two
receptor subunits and some functions, they also provide
distinct and at times contrasting contributions to the life
and death of lymphocytes [15–19]. Although IL-2 is an
important growth and survival factor, it also plays a critical
role in Fas-mediated activation-induced cell death (AICD)
of CD4 T cells [20]. Receptor-mediated stimulation of
CD4 T cells by antigen at high concentration (or by CD3
plus CD28) induces the expression of IL-2 and the IL-2
receptor, which in turn interact to yield T-cell activation
and T-cell cycling. Antigen stimulation of the cycling
T cells at this stage through the T-cell antigen receptor
increases the transcription and surface expression of the
death-effector molecule Fas ligand (FasL). The interaction
of FasL with Fas then leads to death of the self-reactive
T cells [20]. My colleagues and I showed that IL-15, in
contrast, acts to extend the survival of lymphocytes, both
by acting as a growth factor and by inhibiting IL-2-medi-
ated AICD of CD4 T cells [17]. In ex vivo studies, CD4+
T cells from IL-15 transgenic mice that we developed did
not manifest IL-2-mediated AICD.
In addition to their distinct actions on AICD, IL-2 and IL-15
play opposing roles in the homeostasis of CD8+ memory
phenotype T cells [17]. Zhang and Ku and their co-
workers [15,16] reported that the division and survival of
CD8+ T cells of memory phenotype is stimulated by IL-15.
We in turn showed that our transgenic mice had abnor-
mally elevated numbers of CD8+ memory phenotype
T cells. Furthermore, we defined a role for IL-15 and its
receptor in the HTLV-I-associated neurological disease
tropical spastic paraparesis (TSP/HAM) [33]. The number
of circulating MHC class I restricted antigen (amino acids
11–19 of the HTLV-I-encoded tax protein) specific
memory CD8+ cells that have been suggested to be
involved in the pathogenesis of TSP was shown by
tetramer technology to be markedly increased in the circu-
lation of patients with HTLV-I. My colleagues and I studied
the persistence of such CD8-antigen-specific T cells ex
vivo in the presence of antibodies to the IL-2 or IL-15
cytokines or to their receptors and showed that the ex vivo
addition to IL-15 or to IL-2Rβ of antibodies that inhibit
IL-15 action to such mononuclear cells ex vivo led to the
rapid reduction (within six days) in the number of such
antigen-specific memory and effector cytotoxic CD8+
cells, whereas antibodies to IL-2 or to its private IL-2Rα
receptor did not have this effect [33]. In this system, IL-15
both increased the proliferation of the CD8 cells and
reduced their death by apoptosis.
These conclusions concerning the distinct functional roles
manifested by IL-2 and IL-15, derived from ex vivo studies,
are supported by the analysis of knockout mice with dis-
rupted cytokine and cytokine-receptor genes as well as
from the study of transgenic mice. IL-2–/– and IL-2Rα null
mice developed massive enlargement of peripheral lym-
phoid organs and polyclonal T- and B-cell expansion, as
well as autoimmune diseases, including hemolytic anemia
and inflammatory bowel disease, that are related to the
impaired AICD [34,35]. In contrast to this phenotype, mice
genetically deficient in IL-15 (IL-15–/–) or its receptor (IL-
15Rα) did not manifest lymphoid enlargement, high
immunoglobulin levels, or autoimmune disease. Rather, they
displayed a marked reduction in the number of thymic and
peripheral NK cells, NK T cells, and intestinal intraepithelial
lymphocytes (IELs). Furthermore, they manifested a marked
reduction in memory phenotype CD8+ T cells [36,37].
Taken together, these studies support the view that in
their special adaptive immune functions, IL-2 and IL-15
favor opposing actions that tend to emphasize one or the
other of the two competing major goals of the immune
response. IL-2, through its contribution to AICD for CD4
cells and its interference with the persistence of CD8+
memory phenotype T cells, favors the elimination of
selected lymphocytes that are directed toward self-
antigens and thus IL-2 plays a critical role in the maintenance
of peripheral self-tolerance. In contrast, IL-15 through its
inhibition of IL-2-mediated AICD and its positive role in the
maintenance of CD8+ memory phenotype cells, favors the
maintenance and survival of CD4 and CD8 T cells. The
persistence of memory phenotype CD8+ T cells mediated
by IL-15 is of value in maintaining a specific immune
response to foreign pathogens. However, IL-15 expres-
sion carries with it the risk to the organism of the survival
of self-reactive T cells that could lead to the development
of autoimmune diseases.
Aberrant IL-15 expression in retroviral diseases
Increased IL-15 expression has been observed in retroviral
diseases and neoplasia [23,24]. HTLV-I-infected T cells of
patients with the neurological disorder TSP/HAM express
the HTLV-I-encoded transactivator p40tax. The expression
of tax leads to the induction of IL-15 and IL-15Rα, and to
the expression of IL-2 and IL-2Rα. The induction of IL-15
and IL-15R expression involves NF-κB and IRF-1 or inter-
feron regulatory factor (IRF)-4 [23,24,38]. The ex vivo pro-
liferation of HTLV-I-infected T cells in TSP/HAM can be
partially inhibited by an antibody to IL-15 or to IL-2 and can
be virtually abrogated by the simultaneous administration of
antibodies to both cytokines or to both cytokine receptors,
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suggesting that these two cytokines mediate
autocrine/paracrine stimulatory systems as a consequence
of HTLV-I infection. IL-15 also appears to play a role in the
expression of antigen-specific MHC I restricted memory
phenotype CD8+ cells that participate in the pathogenesis
of TSP/HAM. In patients with TSP/HAM, tetramer technol-
ogy showed that 3% to over 20% of their CD8 cells were
MHC class I restricted, antigen-specific cells (directed to
amino acids11–19 of the tax protein transactivator) [33].
The number of such cells that persisted for six days in ex
vivo cultures of patient peripheral blood mononuclear cells
was decreased in the presence of antibodies to IL-15 or to
its receptor. This observation is in accord with the view,
presented above, that IL-15 plays a major role in the gener-
ation and persistence of antigen-specific CD8+ memory
and effector cells. An increased production of IL-15 by
HTLV-I-associated T cells is also observed in ATL, an
aggressive leukemia of mature CD4 cells that is associated
with HTLV-I [23]. Taken as a whole, the evidence supports
the view that the retrovirus-induced IL-15 and its private
receptor play meaningful roles in the pathogenesis and
persistence of both autoimmune and leukemic disorders
associated with HTLV-I infection.
Abnormalities of IL-15 expression in
inflammatory autoimmune diseases 
including RA
Feldmann and co-workers proposed that TNF-α is at the
apex of a cytokine cascade that includes IL-1β, IL-6, GM-
CSF, and a series of inflammatory chemokines, including
Mip1α, Mip1β, and IL-8, that are intimately involved in the
development and progression of RA [1]. McInnes and co-
workers have reported abnormalities of IL-15 in this
disease and have suggested that IL-15 may precede
TNF-α in the cytokine cascade [2,3,8]. In particular, IL-15-
activated T cells can induce TNF synthesis by
macrophages in RA via a mechanism dependent on cell
contact [3]. Those workers reported the presence of high
concentrations of IL-15 in RA synovial fluid and showed
that IL-15 is expressed by cells of the synovial membrane
lining. Nevertheless, the presence of rheumatoid factor in
the fluids may yield specious high estimates for IL-15
assessed by an ELISA. Harada and co-workers showed
that freshly isolated cells from synovial tissues strongly
expressed mRNA for IL-15 and in comparison with cells
from osteoarthritis tissues could spontaneously release
large amounts of IL-15 in culture [4]. The IL-15 could stim-
ulate the proliferation of synovial-tissue T cells from RA
patients. Klimiuk and co-workers also showed high levels
of IL-15 as well as TNF-α in the serum of patients with RA
[7]. Synovial fluids in RA contain chemotactic and T-cell-
stimulatory activities attributable in part to IL-15. Oppen-
heimer-Marks and co-workers showed that IL-15 is
produced by endothelial cells in rheumatoid tissues and
that this cytokine markedly increases transendothelial
migration of both CD4 and CD8 cells [6]. Furthermore,
they showed that IL-15 leads to the accumulation of
T cells in RA synovial tissues engrafted into mice with
severe combined immune deficiency (SCID) in vivo. In a
parallel murine model, the intra-articular injection of IL-15
induced a local tissue inflammatory infiltrate consisting
predominately of T lymphocytes. These data suggest that
IL-15 can recruit and activate T cells into the synovial mem-
brane, possibly contributing to the pathogenesis of RA.
Ziolkowska and co-workers also suggested that IL-15
plays an important role in the pathogenesis of RA, in part
by inducing IL-17 in the joints of RA patients: this cytokine
is known to stimulate synoviocytes to release several medi-
ators of inflammation, including IL-6, IL-8, GM-CSF, and
prostaglandin E2 [39]. Finally, as noted below, the injection
of inhibitors of IL-15 action suppressed the development of
collagen-induced arthritis [9,10]. In summary, these reports
suggest a role for IL-15 in the development of inflammatory
RA and imply that antagonists to IL-15 action may have
therapeutic potential in this disease.
Therapy directed toward IL-15 and IL-15
receptor subunits
The majority of therapeutic trials directed toward the
IL-2/IL-2R or IL-15/IL-15R systems have focused on the
alpha subunit of the IL-2 receptor. Such efforts directed
toward IL-2Rα have met with considerable success in the
treatment of leukemia and select autoimmune disorders
and in the prevention of allograft rejection [40]. However,
efforts targeting IL-2Rα have limitations. In particular, anti-
bodies to IL-2Rα do not inhibit the actions of IL-15, a
cytokine that does not bind to this subunit. They also do
not act on resting NK or NK T cells that express IL-2Rβ and
γc but not IL-2Rα. Additional limitations are suggested by
our discussion above of the role of IL-2R in the elimination
of memory T cells and in AICD, where antibody-mediated
inhibition of AICD may prevent the generation of peripheral
tolerance to host antigens targeted in autoimmunity and to
the transplatation antigens expressed on the allografts. In
addition, the role of IL-2 in the termination of memory cells
directed toward self-antigens is not desirable. Finally,
blockade of IL-2/IL-2R interaction could prevent the devel-
opment and persistence of CD4+CD25+ (IL-2Rα+) nega-
tive regulatory cells that normally would inhibit the
development and maintenance of autoimmune diseases
[41]. Due to these limitations in therapy directed toward IL-
2Rα, therapy directed toward IL-15 receptor is being
developed for use in organ tranplantation protocols and for
application to the treatment of autoimmune disorders, as
well as for diseases caused by the retrovirus HTLV-I. The
administration of an IL-15 inhibitor, the soluble high-infinity
IL-15R receptor chain linked to the immunoglobulin Fc
element, prevented the development of murine collagen-
induced arthritis and inhibited allograft rejection [9]. Fur-
thermore, an IL-15 receptor antagonist produced by
mutation of a glutamine residue within the C-terminus of IL-
15 to aspartic acid competitively inhibited IL-15-triggered
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cellular proliferation [10]. The administration of this IL-15
mutant markedly attenutated antigen-specific delayed
hypersensitivity responses in mice and enhanced the
acceptance of pancreatic islet cell allografts [10].
Our own therapeutic approaches directed toward IL-15
have focused on the IL-2Rβ receptor subunit shared by IL-2
and IL-15 [42]. A humanized version of Mikβ1, an antibody
directed toward IL-2Rβ that is used by both IL-2 and IL-15
and that inhibits IL-15 action on T and NK cells, prolonged
cardiac allograft survival in cynomolgus monkeys [42]. In our
initial clinical trial, we are evaluating the antibody Mikβ1 in
the therapy of patients with T-cell-type large granular lym-
phocytic leukemia associated with hematocytopenia. The
monoclonal large granular lymphocytes involved in this
disease respond to IL-15 and express IL-2Rβ and γc but not
IL-2Rα [43]. In addition, this monoclonal antibody will soon
be evaluated in the treatment of autoimmune diseases
where abnormalities of IL-15 have been demonstrated,
including RA, multiple sclerosis, and TSP/HAM.
Future prospects
Abnormalities of IL-15 expression caused by HTLV-I tax-
mediated transactivation of IL-15 have been demonstrated
in the abnormal T cells in HTLV-I-associated ATL and in
TSP/HAM. Abnormalities of IL-15 expression may also be
involved in the pathogenesis of inflammatory autoimmune
disorders such as RA and inflammatory bowel disease.
Although these observations are interesting, they are not
sufficient to warrant the conclusion that a disorder of IL-15
expression is a meaningful element in the pathogenesis of
these disorders. However, the clinical application of new
therapeutic agents that target IL-15 or the receptor used by
IL-15 may aid in determining if there is a role played by IL-15
in such autoimmune disorders as TSP/HAM and RA. In par-
ticular, IL-15R-directed therapeutic studies of TSP/HAM
would involve tetramer technology to define the effect of
therapy on the number of circulating antigen-specific (tax aa
11–19) CD8+ cells. Similarly, IL-15/IL-15R-directed therapy
of RA should be monitored for its impact on serum concen-
trations of TNF-α and on the activity of the disease.
Additional efforts are directed toward developing an
inhibitor of Janus kinase 3 (JAK3) as an agent for con-
trolled immunosuppression in transplantation protocols
and in the treatment of RA. Expression of JAK3 is limited
largely to lymphocytes and hematopoietic cells. Further-
more, JAK3 is activated by the cytokines that use γc,
including IL-15, IL-2, IL-4, IL-7, IL-9, and IL-21, but is not
essential for signaling by other cytokines. JAK3 is defec-
tive in an autosomal form of severe combined immuno-
deficiency disease (SCID) in humans, in which
immunodeficiency but no disorders of other systems are
found [44,45]. Furthermore, mice made JAK3-deficient by
homologous recombination manifest an absence of NK
cells and abnormalities of T and B cells but do not have
disorders in nonimmunological systems [46]. Finally, JAK3
is constitutively activated in some cell lines in IL-2-inde-
pendent HTLV-I-associated adult T-cell leukemia [47,48].
Taken together, these observations suggest that drugs
that inhibit JAK3 action may be of value as antileukemia
agents and in the therapy of autoimmune diseases, associ-
ated with abnormal production of IL-15.
In conclusion, our emerging understanding of the IL-15/
IL-15R system, including the definition of the actions that
this cytokine manifests – both those that are shared with
IL-2 and those that are distinct – is opening new possibili-
ties for the development of more rational immune interven-
tions directed toward IL-15 and IL-15 receptors that may
be of value in the treatment of cancer, the prevention of
allograft rejection, the therapy of diseases associated with
the retrovirus HTLV-I, and the treatment of autoimmune
diseases such as RA.
Glossary of terms
AICD = activation-induced cell death: a multi-step process
involved in peripheral tolerance, initiated by stimulation of
T-cell receptors (TCRs)/CD3 and inducing the expression
and interaction of the induced IL-2 and IL-2 receptors
(IL-2Rs). When the cell cycling induced by this interaction
is followed by restimulation of TCR/CD3, these events lead
to the induction of the cell-death-effector Fas ligand, which
interacts with the Fas receptor, culminating in the death of
the self-reactive T cell; ATL = adult T-cell leukemia: an
aggressive malignancy of mature lymphocytes expressing
CD3, CD4, and CD25 (IL-2Rα), caused by the retroviruses
HTLV-I; FasL = Fas ligand; HTLV-I = human T-cell lympho-
tropic virus I: a retrovirus, found predominantly in Japan,
the Caribbean Islands, and sub-Saharan Africa, which
induces the expression of IL-2, IL-15, and their private
receptors and which is the etiological agent of a number of
human diseases including inflammatory arthritis, myositis,
adult T-cell leukemia, and the neurological disorder tropical
spastic paraparesis/HTLV-I-associated myelopathy (TSP/
HAM); IL-15Rα = cytokine-specific private receptor for
IL-15; IL-2Rα = cytokine-specific private receptor for IL-2;
tax = transactivator (protein); TSP/HAM = tropical spastic
paraparesis/HTLV-I-associated myelopathy: a demyelinat-
ing neurological disease caused by the retrovirus HTLV-I
and associated with progressive weakness and bowel and
bladder dysfunction.
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